Business Wire

TX-OMNITRACS

9.9.2020 14:02:05 CEST | Business Wire | Press release

Share
Omnitracs Expands Its Platform Offering With Acquisition of SmartDrive

Omnitracs, LLC , a leader in SaaS-based fleet management and data analytics solutions and a pioneer in transportation technology, and SmartDrive, a leader in video-based safety and transportation intelligence, today announced that they have entered into a definitive agreement for Omnitracs to acquire SmartDrive. The combined company will bring together two transportation technology leaders to offer an industry-first converged, end-to-end platform that optimizes safety, driver productivity and workflow, as well as routing, dispatch and compliance.

Pervasive connectivity, advanced hardware, and the power of artificial intelligence (AI) and machine learning (ML) are just a few of the technology advancements that promise to unlock value and improve efficiency across all aspects of the $60B transportation technology industry. Unlocking that value in the highly fragmented fleet business, however, requires sufficient data and correlation. The new combined company will, for the first time, unite driving context with operational insight across hundreds of billions of data points to transform the experience for the driver, back office, and customer service alike.

“By integrating SmartDrive’s unparalleled transportation intelligence platform, video safety hardware and risk analysis service offering with the Omnitracs One platform, we can deliver a converged solution built on AI and ML that redefines the future of commercial transportation today. Real-time risk mitigation, streamlined data flows from the cab and vehicle sensors to dispatch and the back office, and a superior driver experience will be brought together to improve safety, efficiency and operational excellence,” said Ray Greer, Chief Executive Officer, Omnitracs. “We have long admired SmartDrive’s customer-centric approach to technology innovation and world class support and service. We look forward to welcoming the talented SmartDrive team to the Omnitracs family.”

There is no one-size-fits all solution for today’s fleets: the needs of oil and gas operations are very different from those of general freight – and both differ from local delivery and dozens of other transportation operations. Both Omnitracs and SmartDrive have built their businesses around providing enterprise-grade, flexible and adaptive solutions that can anticipate and address the distinct operating requirements of each fleet they serve. Together, their depth of experience across decades of partnerships will enable the combined company to uniquely support complexity at scale.

“We couldn’t be more excited about joining forces with Omnitracs and look forward to realizing and advancing the promise of convergence to the benefit of our shared customers,” stated Steve Mitgang, Chief Executive Officer, SmartDrive. “In Omnitracs, we have a like-minded company, seeing the power of data for innovation and solving material fleet and transportation industry challenges.”

The COVID-19 pandemic has underscored the significant role of commercial drivers, as the trucking sector has been instrumental to ensuring the availability of critical medical supplies and equipment, as well as essential consumer goods. Given the long-standing shortage of qualified drivers and high turnover rates, creating and sustaining a favorable driver experience (DX) is imperative to fleets’ success. However, recent transportation technology advancements have resulted in a proliferation of devices and sensors, the need for multiple cellular connections, siloed data streams that create redundancies, and other inefficiencies that stem from disparate onboard and back-office systems, all of which complicated the DX.

SmartDrive’s proven video-based safety program integrated with Omnitracs’ best-in-class driver workflow and complemented by the companies’ unmatched years of collective transportation intelligence present an opportunity to streamline and enhance DX. The combined company will deliver the most complete and intelligent DX with the right in-cab and back-office decision making, alerting, and driver coaching – a virtual co-pilot that will lead to significant safety, fuel efficiency, operational and financial gains for fleets.

“We’ve had great partnerships with both Omnitracs and SmartDrive over the years. We are excited to see these two companies come together,” said Chad England, Chief Executive Officer, C.R. England, Inc. “We are confident that the integration of offerings will create efficiencies for C.R. England. We congratulate both Omnitracs and SmartDrive on their new relationship and look forward to the future.”

Subject to customary closing conditions, including customary regulatory approval, the deal is expected to close later in calendar Q3 or Q4. Kirkland & Ellis LLP advised Omnitracs on the acquisition. PJT Partners is serving as exclusive financial advisor and Pillsbury Winthrop Shaw Pittman LLP is serving as legal counsel to SmartDrive.

About SmartDrive

SmartDrive Systems gives fleets and drivers unprecedented driving performance insight and analysis, helping save fuel, expenses and lives. Its video safety, predictive analytics, telematics, compliance and personalized performance program help fleets improve driving skills, lower operating costs and deliver significant ROI. With an easy-to-use managed service, fleets and drivers can access and self-manage driving performance anytime, anywhere. The company, which is ranked as one of the fastest growing companies by Deloitte’s Technology Fast 500™ for six consecutive years, has recorded nearly 25 billion miles and compiled the world’s largest storehouse of more than 300 million analyzed risky-driving events. SmartDrive Systems is based in San Diego, Calif., and employs over 725 people worldwide.

About Omnitracs, LLC

Omnitracs, LLC is the global pioneer of trucking solutions for all business models. Omnitracs’ more than 1,100 employees deliver software-as-a-service-based solutions to help over 14,000 customers manage nearly 1,100,000 assets in more than 70 countries. The company pioneered the use of commercial vehicle telematics 35 years ago and serves today as a powerhouse of innovative, intuitive technologies. Omnitracs transforms the transportation industry through technology and insight, featuring best-in-class solutions for compliance, safety and security, productivity, telematics and tracking, transportation management (TMS), planning and delivery, data and analytics, and professional services.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye